Program Director: John V. Heymach, MD, PhD, Professor and Chair, Department of Thoracic/Head & Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
October 27, 2018 Houston Marriott at the Texas Medical Center, 6580 Fannin Street, Houston, TX 77030; Phone: 713-796-0080
Jointly Provided by
Merck Sharp & Dohme Corp.
AstraZeneca Pharmaceuticals LP
For online registration and more information visit: www.cancernetus.com
This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in non-small cell lung cancer and head & neck cancer. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.
Statement of Need/Program Overview
This symposium is intended to improve care of patients with non-small cell lung cancer and head & neck cancer by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.
• Select NSCLC patients based on new molecular profiling for personalized chemotherapy
• Outline the clinical data on the use of epidermal growth factor receptor (EGFR) and EGFR-T790M–inhibitors in the treatment of NSCLC
• Identify strategies to overcome secondary or acquired resistance to EGFR-positive and EGFR-T790M–positive NSCLC
• Outline the clinical data on the optimal use of anti-PD-1 and PD-L1 antibodies in the treatment of NSCLC
• Outline the clinical data on the optimal use of anti-PD-1, PD-L1 antibodies and combination approaches in the treatment of NSCLC
• Outline the mechanisms of action of PD-1 and PD-L1 blockade in SCCHN with high mutational burden and implication of immune resistance in SCCHN
• Evaluate PD-1/PD-L1 interactions that contribute to better outcomes for patients with SCCHN
• Identify strategies in the treatment of NSCLC patients with ALK inhibitors
• Identify strategies to overcome secondary or acquired ALK TKI resistance in patients with NSCLC
Don L. Gibbons, MD, PhD, Assistant Professor, Depts. of Thoracic, Head/Neck Medical Oncology & Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
John V. Heymach, MD, PhD, Professor and Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Tanguy Y. Seiwert, MD, Assistant Professor, Head & Neck and Lung Cancer Division, The University of Chicago Medicine, Chicago, IL
Registration fee includes buffet breakfast, lunch and syllabus book.
|Early Registration Fee
(Up to 10/05/18)
|Discounted Registration Fee
(10/06/18 to 10/22/18)
|Regular Registration Fee
(10/23/18 to 10/27/18)
*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions
Payment may be made: MC Visa Discover Check
Credit Card Number___________________________ Expiration Date_______________
Name and address________________________________________________________
as given on the monthly credit card statement
No refund. Substitution is allowed.
Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057
To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. For questions if any please call Brian Waggoner at 972-459-5222 or E-mail: email@example.com
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this live activity for a maximum of 6 AMA PRA Category 1 CreditsTM for physicians, 6 contact hours for nurses and 6 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.